3FV7EH3G97 | 169673-60-3

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 香豆素及其衍生物
• 英文名称: 3FV7EH3G97
• 英文别名: N-[(2S,3R,4R,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-2-(7-hydroxy-2-oxochromen-6-yl)oxyoxan-3-yl]acetamide
• CAS: 169673-60-3
• 化学式: C₁₇H₁₉NO₉
• 分子量: 381.339
• InChiKey: OTXAWKXSJDFGID-LMHBHQSJSA-N

物化性质

• 沸点：
  802.7±65.0 °C(Predicted)
• 密度：
  1.60±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.6
• 重原子数：
  27
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.41
• 拓扑面积：
  155
• 氢给体数：
  5
• 氢受体数：
  9

文献信息

• COMBINATION THERAPY OF ARTHRITIS WITH TRANILAST
  申请人：PEARLMAN Rodney

  公开号：US20100158905A1

  公开（公告）日：2010-06-24

  Combination therapy is disclosed herein for the treatment an arthritic condition (e.g. rheumatoid arthritis, osteoarthritis or psoriatic arthritis). The therapies disclosed herein comprise administering tranilast or an analogous compound in combination with a pharmaceutical agent, such as a non-steroidal anti-inflammatory drug, a disease-modifying drug, a COX-2 inhibitor, an antibiotic, an analgesic or combination thereof.

  本文披露了一种治疗关节炎症状（例如类风湿性关节炎、骨关节炎或银屑病性关节炎）的联合治疗方案。本文所披露的治疗方案包括与药物剂量联合使用曲安那或类似化合物，例如非甾体抗炎药、疾病修饰药、COX-2抑制剂、抗生素、镇痛药或以上药物的联合使用。
• [EN] METHOD FOR INHIBITING FIBROCARTILAGE DEGRADATION<br/>[FR] PROCEDE VISANT A INHIBER LA DEGRADATION DU CARTILAGE FIBREUX
  申请人：UNIV RUSH MEDICAL CENTER

  公开号：WO2005091960A2

  公开（公告）日：2005-10-06

  Described herein is a method for inhibiting cartilage, typically fibrocartilage, degradation using esculetin and chemically related compounds. In some embodiments, the esculetin compound is used to prevent degradation of intervertebral disc tissues.
• [EN] COMBINATION THERAPY FOR ARTHRITIS WITH TRANILAST<br/>[FR] COMBINAISON THÉRAPEUTIQUE POUR L'ARTHRITE AVEC DU TRANILAST
  申请人：NUON THERAPEUTICS INC

  公开号：WO2010071866A2

  公开（公告）日：2010-06-24

  Combination therapy is disclosed herein for the treatment an arthritic condition (e.g. rheumatoid arthritis, osteoarthritis or psoriatic arthritis). The therapies disclosed herein comprise administering tranilast or an analogous compound in combination with a pharmaceutical agent, such as a non-steroidal anti-inflammatory drug, a disease-modifying drug, a COX -2 inhibitor, an antibiotic, an analgesic or combination thereof.